Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma Steps Out Of Colchicine Sales Ban Shadow, Maintains 20 Percent Growth Forecast

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA's ban on unapproved colchicine will cut deeply into Jordanian drug maker Hikma's profits and could present some obstacles to the company. However, the London Stock Exchange-listed company vows to maintain an estimated 20 percent growth and expects to continue penetration for its core products in the U.S. generics market

You may also be interested in...



As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position

For a company like Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time. The political instability in many countries, especially in Egypt and Tunisia, has hurt Hikma's growth and profitability in the first six months

As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position

For a company like Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time. The political instability in many countries, especially in Egypt and Tunisia, has hurt Hikma's growth and profitability in the first six months

As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position

For a company like Jordan-based Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time.

Related Content

UsernamePublicRestriction

Register

SC073355

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel